

# Europe Industry Sector M&A & Valuation TLDR - 2025-12-17

*Europe Industry Sector*

*Generated on 2025-12-17*

*CONFIDENTIAL - FOR INTERNAL USE ONLY*

## 1. 30-Second TL;DR

- 
- Workhorse Group merged with Motiv Electric Trucks to create a leading North American medium-duty electric truck manufacturer, targeting a \$23 billion market.
  - AEON Biopharma executed a \$15 million exchange agreement with Daewoong Pharmaceutical to strengthen its capital structure and support its BOTOX biosimilar development.
  - The European banking sector is cautiously optimistic, with an average P/E ratio of 12.5x, driven by regulatory simplifications and economic resilience.

## 2. 1-Minute TL;DR

- 
- Workhorse Group's merger with Motiv Electric Trucks aims to establish a dominant position in the medium-duty electric truck market, leveraging Motiv's manufacturing capabilities. The deal size is undisclosed, but it targets a \$23 billion market.
  - AEON Biopharma's \$15 million exchange agreement with Daewoong Pharmaceutical focuses on eliminating debt and enhancing financial stability for its BOTOX biosimilar project.
  - The European banking sector is navigating a cautious landscape, with an average P/E ratio of 12.5x, reflecting optimism due to regulatory simplifications by the ECB. However, economic uncertainties and regulatory complexities remain challenges.

## 3. 2-Minute TL;DR

- 
- Workhorse Group's merger with Motiv Electric Trucks, announced on December 15, 2025, aims to create a leading North American manufacturer in the medium-duty electric truck space, targeting a market worth approximately \$23 billion. While specific deal values and valuation multiples are not disclosed, the merger is expected to enhance Workhorse's market position through Motiv's established customer relationships and manufacturing capabilities. However, integration and market competition pose risks.
  - AEON Biopharma's execution of a \$15 million exchange agreement with Daewoong Pharmaceutical is designed to strengthen its capital structure by eliminating over 90% of its outstanding debt, facilitating

# **Europe Industry Sector M&A & Valuation TLDR - 2025-12-17**

## *Europe Industry Sector*

its entry into the biosimilar market with ABP-450. The deal's success hinges on regulatory approvals and navigating a competitive landscape.

- The European banking sector is characterized by cautious optimism, with major banks trading at an average P/E ratio of 12.5x, reflecting a slight premium over historical averages. The ECB's proposals to simplify capital rules are seen as a positive step towards enhancing competitiveness, although regulatory complexities and economic uncertainties continue to pose challenges. Analysts suggest that while regulatory changes are necessary, they must ensure banks remain resilient to future shocks.